Biotech - Tons of startups, most dismal failures, financial nightmares, long time for pipeline to reach any credible point of expecting a success instead of a failure in clinical trials.
I believe what I described above is a pretty accurate view of biotech to most investors, especially institutional investors, so why would any investor pay close attention to any biotech until it has reached at least a culmination of P2 clinical trials? What would any investor care about what a CEO was spouting when his product was years from getting to P2 trials? I don't think they even start looking at a startup biotech until P3 trials as evidenced by IPIX institutional listing of current investors recently showing minimal investment by only about two or three marginal clients, not counting Aspire.
Now if the above is true which IMO is pretty much a given, how much validity do you really think there is to the cry of Leo having no cred in the market based on history of 2-5 years ago? It's not like he wiped out a load of investors with a reverse split or other such dastardly deeds. No institutional acct lost money and the only money retail lost was that of uninformed investors that didn't realize the time frame or financial challenges a bio startup faces in its beginning years. Those that lost big sadly lost due to their own inexperience or ignorance of how the game is played by ruthless short MM's and other professional firms that legally fleece the inexperienced investor. Can anyone spell MAKO?
IPIX/CTIX really only came to some visibility about the time of the name change in my estimation as that is when we got the positive news/pics of the B-UP/UPS trial.
We should add to the picture by early Dec when we report top line results of B-OM and that is going to validate the B platform as a monster for both antibiotic (ABSSSI success) and anti-inflammatory conditions (UP/UPS, OM) plus the recent sponsorship of a nice dermatology conference gives some recognition for B as a possible major player in the dermatology arena (acne, eczema, and the more egregious forms of skin problems).
Dec continues with an update on K-OC MOA findings and will bolster Kevetrin as a possible super player in the p53 activation search and as a major combo player for new cancer treatments. This could be a game changer drug for cancer if the results prove what Dr. M expects them to prove. There are a number of esteemed Dr's that believe in K and I hope this is the trial that finally kicks its progress to commercialization into high gear.
We finish the month with conclusion of P with no remarks about major safety issues and we wait a couple of months IMO to get top line data. Again, possible major first in class possibility based on negligible safety issues, low cost, and high efficacy which many here expect to see as results of the P2B.
I say take all the talk of 2 years ago and later and shove it where the sun don't shine as it is not part of the story any longer. Start discussing events today but that would be hard to swallow for all those trying to paint IPIX in a negative light for their own agendas.
If I was a new institutional acct looking at IPIX, I would be impressed with how many high revenue products are nearly finished with P2 results as opposed to caring about some comment Leo made 4 or 5 years ago.
